151 related articles for article (PubMed ID: 33880760)
21. Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects.
Luedtke D; Marzin K; Jungnik A; von Wangenheim U; Dallinger C
Eur J Drug Metab Pharmacokinet; 2018 Oct; 43(5):533-541. PubMed ID: 29500603
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism.
Lau YY; Okochi H; Huang Y; Benet LZ
Drug Metab Dispos; 2006 Jul; 34(7):1175-81. PubMed ID: 16624870
[TBL] [Abstract][Full Text] [Related]
23. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.
Lee CK; Choi JS; Choi DH
Pharmacol Rep; 2015 Feb; 67(1):44-51. PubMed ID: 25560574
[TBL] [Abstract][Full Text] [Related]
24. Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition.
Gu X; Wang L; Gan J; Fancher RM; Tian Y; Hong Y; Lai Y; Sinz M; Shen H
Drug Metab Dispos; 2020 Aug; 48(8):724-734. PubMed ID: 32482623
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of fluvastatin in subjects with renal impairment and nephrotic syndrome.
Appel-Dingemanse S; Smith T; Merz M
J Clin Pharmacol; 2002 Mar; 42(3):312-8. PubMed ID: 11865968
[TBL] [Abstract][Full Text] [Related]
26. Rifampin Reduces the Plasma Concentrations of Oral and Intravenous Hydromorphone in Healthy Volunteers.
Lohela TJ; Poikola S; Neuvonen M; Niemi M; Backman JT; Olkkola KT; Lilius TO
Anesth Analg; 2021 Aug; 133(2):423-434. PubMed ID: 33177323
[TBL] [Abstract][Full Text] [Related]
27. Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2.
Lindahl A; Sjöberg A; Bredberg U; Toreson H; Ungell AL; Lennernäs H
Mol Pharm; 2004; 1(5):347-56. PubMed ID: 16026004
[TBL] [Abstract][Full Text] [Related]
28. Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics.
Becquemont L; Neuvonen M; Verstuyft C; Jaillon P; Letierce A; Neuvonen PJ; Funck-Brentano C
Clin Pharmacol Ther; 2007 May; 81(5):679-84. PubMed ID: 17301736
[TBL] [Abstract][Full Text] [Related]
29. Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers.
Ridtitid W; Wongnawa M; Mahatthanatrakul W; Chaipol P; Sunbhanich M
J Pharm Pharmacol; 2000 Oct; 52(10):1265-9. PubMed ID: 11092571
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
Neuvonen PJ; Backman JT; Niemi M
Clin Pharmacokinet; 2008; 47(7):463-74. PubMed ID: 18563955
[TBL] [Abstract][Full Text] [Related]
31. The interaction of diltiazem with lovastatin and pravastatin.
Azie NE; Brater DC; Becker PA; Jones DR; Hall SD
Clin Pharmacol Ther; 1998 Oct; 64(4):369-77. PubMed ID: 9797793
[TBL] [Abstract][Full Text] [Related]
32. Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects.
Dawra VK; Sahasrabudhe V; Liang Y; Matschke K; Shi H; Hickman A; Saur D; Terra SG; Cutler DL
Clin Ther; 2018 Sep; 40(9):1538-1547. PubMed ID: 30170758
[TBL] [Abstract][Full Text] [Related]
33. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.
Keskitalo JE; Kurkinen KJ; Neuvonen M; Backman JT; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2009 Aug; 68(2):207-13. PubMed ID: 19694740
[TBL] [Abstract][Full Text] [Related]
34. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.
Keskitalo JE; Pasanen MK; Neuvonen PJ; Niemi M
Pharmacogenomics; 2009 Oct; 10(10):1617-24. PubMed ID: 19842935
[TBL] [Abstract][Full Text] [Related]
35. The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.
Yee KL; Khalilieh SG; Sanchez RI; Liu R; Anderson MS; Manthos H; Judge T; Brejda J; Butterton JR
Clin Drug Investig; 2017 Jul; 37(7):659-667. PubMed ID: 28353169
[TBL] [Abstract][Full Text] [Related]
36. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
[TBL] [Abstract][Full Text] [Related]
37. Clinical pharmacokinetics of fluvastatin.
Scripture CD; Pieper JA
Clin Pharmacokinet; 2001; 40(4):263-81. PubMed ID: 11368292
[TBL] [Abstract][Full Text] [Related]
38. Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study.
Tran JQ; Zhang P; Ghosh A; Liu L; Syto M; Wang X; Palmisano M
Adv Ther; 2020 Oct; 37(10):4381-4395. PubMed ID: 32857315
[TBL] [Abstract][Full Text] [Related]
39. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
[TBL] [Abstract][Full Text] [Related]
40. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]